Stock listing
A2AC4K Stock Price, News, Filings & Events — Editas Medicine, Inc.
Selected listing: A2AC4K · LS · EUR · DE
This page tracks Editas Medicine, Inc.'s A2AC4K:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2AC4K:LS. A2AC4K:LS is the stock-level entry point for investors researching Editas Medicine, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Editas Medicine, Inc. is a public biotechnology company based in America, focused on developing transformative genomic medicines. The company's market capitalization is approximately $399 million. Editas is engaged in advancing its proprietary gene-editing technology to address various genetic diseases.
- Ticker
- A2AC4K:LS
- Asset type
- Stock
- Market cap
- $414.7M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LS
- Currency
- EUR
Editas Medicine, Inc. A2AC4K:LS stock context
This page tracks Editas Medicine, Inc.'s A2AC4K:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2AC4K:LS. A2AC4K:LS is the stock-level entry point for investors researching Editas Medicine, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Editas Medicine, Inc. is a public biotechnology company based in America, focused on developing transformative genomic medicines. The company's market capitalization is approximately $399 million. Editas is engaged in advancing its proprietary gene-editing technology to address various genetic diseases.
Latest news from Editas Medicine, Inc.
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
September 8, 2026
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
August 5, 2026
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
August 4, 2026
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
May 28, 2026
Editas Medicine Announces Proposed Public Offering
May 26, 2026
Editas Medicine, Inc. earnings calls
Editas Medicine, Inc. (EDIT) Q2 2024 Earnings Call
August 7, 2024 · Replay with transcript and chapters
Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call
May 8, 2024 · Replay with transcript and chapters
Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call
February 28, 2024 · Replay with transcript and chapters
Editas Medicine, Inc. (EDIT) Q3 2023 Earnings Call
November 28, 2023 · Replay with transcript and chapters
Editas Medicine, Inc. (EDIT) Q2 2023 Earnings Call
August 2, 2023 · Replay with transcript and chapters
Editas Medicine, Inc. (EDIT) Q1 2023 Earnings Call
May 5, 2023 · Replay with transcript and chapters
Research Editas Medicine, Inc.
Editas Medicine, Inc. investor report
Review AI stock analysis and investor report context for A2AC4K:LS.
Editas Medicine, Inc. company profile
View the public company page for Editas Medicine, Inc. on 6ix.
Editas Medicine, Inc. news
Read company news and market updates connected to Editas Medicine, Inc..
Editas Medicine, Inc. investor events
Find investor webinars, events, and replay context for Editas Medicine, Inc..
Alternate listings
EDIT:NASDAQ
US · USD
Alternate listing for Editas Medicine, Inc.; the primary context on this page is A2AC4K:LS.
8EM:GETTEX
DE · EUR
Alternate listing for Editas Medicine, Inc.; the primary context on this page is A2AC4K:LS.
EDIT:BOATS
US · USD
Alternate listing for Editas Medicine, Inc.; the primary context on this page is A2AC4K:LS.
8EM:TRADEGATE
DE · EUR
Alternate listing for Editas Medicine, Inc.; the primary context on this page is A2AC4K:LS.
A2AC4K:LSX
DE · EUR
Alternate listing for Editas Medicine, Inc.; the primary context on this page is A2AC4K:LS.
8EM:SWB
DE · EUR
Alternate listing for Editas Medicine, Inc.; the primary context on this page is A2AC4K:LS.
0IFK:LSE
GB · USD
Alternate listing for Editas Medicine, Inc.; the primary context on this page is A2AC4K:LS.
8EM:FWB
DE · EUR
Alternate listing for Editas Medicine, Inc.; the primary context on this page is A2AC4K:LS.
8EM:BX
CH · CHF
Alternate listing for Editas Medicine, Inc.; the primary context on this page is A2AC4K:LS.
8EM:DUS
DE · EUR
Alternate listing for Editas Medicine, Inc.; the primary context on this page is A2AC4K:LS.
8EM:HAM
DE · EUR
Alternate listing for Editas Medicine, Inc.; the primary context on this page is A2AC4K:LS.
8EM:MUN
DE · EUR
Alternate listing for Editas Medicine, Inc.; the primary context on this page is A2AC4K:LS.